Nociceptin attenuates opioid and γ-aminobutyric acidB receptor-mediated analgesia in the mouse tail-flick assay
Section snippets
Acknowledgements
We would like to thank Dr Ennio Ongini for his critical comments on the manuscript.
References (20)
- et al.
Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more
Trends Neurosci.
(1998) - et al.
Functional blockade of opioid analgesia by orphanin FQ/nociceptin
Biochem. Pharmacol.
(1998) - et al.
Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ, Neurosci.
Lett.
(1996) - et al.
ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization
FEBS Lett.
(1994) - et al.
Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities
J. Biol. Chem.
(1998) - et al.
Naloxone sensitive orphanin FQ-induced analgesia in mice
Eur. J. Pharmacol.
(1996) GABAergic mechanisms of analgesia: an update
Pharmacol. Biochem. Behav.
(1987)- et al.
Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry
Annu. Rev. Neurosci.
(1984) - et al.
Nociceptin and the ORL-1 ligand [Phe1ψ(CH2-NH)Gly2]nociceptin(1–13)NH2 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain
Br. J. Pharmacol.
(1999) - et al.
Orphanin FQ acts as a supraspinal, but not a spinal, anti-opioid peptide
NeuroReport
(1996)
Cited by (12)
Nociceptin/orphanin FQ blocks the antinociception induced by mu, kappa and delta opioid agonists on the cold water tail-flick test
2007, European Journal of PharmacologyAn investigation of binding sites for paracetamol in the mouse brain and spinal cord
2005, European Journal of PharmacologyOrphanin FQ/nociceptin: From neural circuitry to behavior
2003, Life SciencesCitation Excerpt :or in specific brain regions known to mediate the analgesic actions of μ-opioid drugs. OFQ/N also attenuates opioid and non-opioid stress-induced analgesia and acupuncture analgesia, and interferes with the analgesic effects of the alpha2-adrenergic agonist clonidine and the GABAB agonist baclofen (Mogil et al., 1996a,b; King et al., 1998; Suaudeau et al., 1998; Wang et al., 1999b; Citterio et al., 2000; Grisel and Mogil, 2000; Rizzi et al., 2001b). In contrast, as discussed in depth in a recent review (Mogil and Pasternak, 2001), the reported effects of OFQ/N per se on nociceptive responses are quite varied.
- 1
Present address: ENDO Pharmaceuticals Inc., 1333 Campus Parkway Neptune, NJ, USA.